Profile data is unavailable for this security.
About the company
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
- Revenue in GBP (TTM)0.00
- Net income in GBP-953.00k
- Incorporated2007
- Employees67.00
- LocationCizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 207 469 0930
- Fax+44 238 123 0382
- Websitehttps://cizzlebiotechnology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 3.81m | 7.00 | -- | 1.72 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| IXICO PLC | 6.67m | -1.18m | 3.93m | 89.00 | -- | 0.3436 | -- | 0.5894 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ValiRx Plc | 0.00 | -2.41m | 4.30m | 8.00 | -- | 0.791 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 4.91m | 4.00 | -- | 1.01 | -- | 379.33 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -953.00k | 6.54m | 67.00 | -- | 2.29 | -- | -- | -0.003 | -0.003 | 0.00 | 0.0072 | 0.00 | -- | -- | -- | -35.53 | -134.34 | -37.22 | -227.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 76.74 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.18m | 7.17m | 0.00 | -- | 3.49 | -- | -- | -0.004 | -0.004 | 0.00 | 0.0059 | 0.00 | -- | -- | -- | -48.01 | -- | -51.61 | -- | -- | -- | -- | -- | -- | -6,299.75 | 0.00 | -- | -- | -- | -35.13 | -- | -- | -- |
| ImmuPharma PLC | 69.96k | -2.99m | 8.50m | 13.00 | -- | 3.91 | -- | 121.43 | -0.0092 | -0.0092 | 0.0002 | 0.0052 | 0.0227 | -- | 0.1706 | 5,381.54 | -97.05 | -89.69 | -159.35 | -106.57 | -- | -- | -4,275.31 | -7,958.69 | -- | -2.40 | 0.00 | -- | -100.00 | -- | 53.42 | -- | 32.98 | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 9.40m | 91.00 | -- | 1.01 | -- | 1.04 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.33m | 9.49m | 10.00 | -- | 2.68 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0428 | 0.00 | -- | -- | 0.00 | -50.56 | -- | -57.49 | -- | -- | -- | -- | -- | -- | -- | 0.1267 | -- | -- | -- | -6.71 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Unicorn Asset Management Ltd.as of 31 Mar 2024 | 34.20k | 0.01% |
